Investing in Genepharm will give you the opportunity to participate in one of the world's fastest growing generic pharmaceutical markets in Australia, with greater than 20% compound annual growth forecast over the next five years.

With access to an extensive portfolio of generic and branded pharmaceuticals, OTC healthcare products and dermo-cosmetics Genepharm Australasia is a leading supplier to Australian pharmacies.

ABN AMRO Morgans - Entry into Asia
11 February 2008

GAA has acquired Strides Arcolab for A$65m (8.8x FY08F EBITDA). This purchase appears strategically sound and should be 6%+ EPS accretive. While a step in the right direction, given the absence of clear catalysts, we remain cautious on GAA. Hold.(Read full PDF)

Read more

Download 2008 Annual Report

Download 2008 Annual Report - PDF (1,380kB)